Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.65 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957115 | 0.92 | CHRNA7 (0.76) | CHRNA7METAP2KCNH2EPHX1CYP2D6 | |
| SCHEMBL23957090 | 0.85 | CHRNA7 (0.55) | CHRNA7METAP2KCNH2EPHX1CYP2D6 | |
| SCHEMBL23957138 | 0.82 | CHRNA7 (0.86) | CHRNA7 | |
| SCHEMBL23957161 | 0.80 | CHRNA7 (0.83) | CHRNA7METAP2KCNH2HDAC8HDAC6 | |
| SCHEMBL23928886 | 0.79 | CHRNA7 (0.79) | CHRNA7METAP2KCNH2HDAC8HDAC6 | |
| SCHEMBL23928853 | 0.79 | CHRNA7 (1.00) | CHRNA7 | |
| SCHEMBL30094734 | 0.79 | CHRNA7 (0.61) | CHRNA7KCNH2HDAC8HDAC6HSD11B1 | |
| SCHEMBL23957140 | 0.78 | TRPM8 (0.53) | CHRNA7KCNH2EPHX1CYP2D6EPHX2 | |
| SCHEMBL23957165 | 0.78 | CHRNA7 (0.68) | CHRNA7HDAC8HDAC6HSD11B1 | |
| SCHEMBL23928859 | 0.78 | CHRNA7 (0.79) | CHRNA7HDAC8HDAC6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | CHRNA7, CHRM3, ADRB3 | CHRNA7 1/4885METAP2 3661/4885KCNH2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.